R1 RCM

The largest end-to-end RCM operator

Our take

R1 RCM is one of the two dominant end-to-end revenue cycle outsourcers for US health systems. Founded in 2003 as Accretive Health, it manages everything from scheduling and registration through coding, billing, denials, and payment recovery, often taking over a health system's revenue cycle staff entirely. Long-term exclusive partnerships with Ascension and Intermountain Health anchor a client base that touches 94 of the top 100 health systems, and its Cloudmed acquisition added a revenue intelligence layer that mines clinical data for missed reimbursement.

TowerBrook and CD&R took R1 private in November 2024 at an $8.9 billion valuation, and in March 2025 the company launched R37, an AI lab built in exclusive partnership with Palantir, aiming agentic AI at coding, billing, and denials using R1's repository of 180 million annual payer transactions and 550 million patient encounters. For a large health system wanting to hand off the entire revenue cycle, R1 is one of two default choices. The commitment is heavy, though: these are long contracts with deep operational entanglement, and the company's scale cuts both ways when service issues arise.

What it does

Full outsourced revenue cycle operations, front door to final payment
Patient access, scheduling, and registration services at scale
Coding, billing, denials management, and underpayment recovery
Cloudmed revenue intelligence mines charts for missed revenue
R37 lab building agentic AI for coding and denials
Modular offerings for physician groups and hospitals

Where it's strong

Unmatched scale and data: serves 94 of the top 100 health systems and processes 550 million patient encounters a year.
Can take over the entire revenue cycle including staff, which few vendors can credibly offer a large health system.
The exclusive Palantir partnership (R37) gives it a serious platform for agentic AI across coding, billing, and denials.

What buyers should weigh

Full outsourcing means deep operational dependence; unwinding an R1 contract is a multi-year project.
Built for large health systems; small and mid-size groups are not the core market and get less attention.
PE ownership after the $8.9B take-private adds margin pressure, and the company has weathered customer disputes and a 2024 cyberattack ripple from partners.

Latest

Launched R37, an AI lab in exclusive partnership with Palantir, in March 2025 to build agentic AI for coding, billing, and denials, following its $8.9B take-private by TowerBrook and CD&R in November 2024.